Skip to main content

Table 1 Base-line characteristics of the patients (intention-to-treat population).

From: Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

Characteristic* Interferon and Ribavirin 6 mo (n = 40) Ribavirin 6 mo (n = 40) Placebo 6 mo (n = 37)
Age – yr 47 ± 12 48 ± 12 46 ± 12
Sex – M/F 28/12 28/12 31/6
Serum ALT – times ULN 3.8 ± 2.0 3.8 ± 2.0 3.7 ± 1.6
Serum HCV RNA    
Copies/ml – log10 6.2 ± 0.8 6.3 ± 0.8 6.3 ± 0.7
≥2 × 106 copies/ml – % 54 55 55
Genotype – n (%)    
1 29 (79) 24 (62) 28 (76)
2 or 3 6 (16) 11 (22) 8 (23)
other 2 (5) 4 (6) 1 (3)
Cirrhosis – n (%) 18 (45) 13 (33) 14 (38)
  1. *means ± SD. Assessed by bDNA in 68 patients (24 interferon+ribavirin, 22 ribavirin, 22 placebo).